Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Oryzon Genomics SA ( (ES:ORY) ).
Oryzon Genomics SA has announced a capital increase of 25 million euros through an accelerated private placement of ordinary shares. The funds will be used to enhance clinical development in CNS diseases and oncology, prepare for drug manufacturing, and strengthen the balance sheet for potential partnerships and Nasdaq listing.
More about Oryzon Genomics SA
Oryzon Genomics SA is a company operating in the biotechnology industry, focusing on clinical development in central nervous system diseases, oncology, and hematology. The company is also involved in drug manufacturing preparations and aims to strengthen its financial position for potential partnerships and mergers.
YTD Price Performance: 79.67%
Average Trading Volume: 2,671
Technical Sentiment Signal: Sell
Current Market Cap: €190.9M
For detailed information about ORY stock, go to TipRanks’ Stock Analysis page.